Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/131008
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin |
Author: | Harder, J.M. Guymer, C. Wood, J.P.M. Daskalaki, E. Chidlow, G. Zhang, C. Balasubramanian, R. Cardozo, B.H. Foxworth, N.E. Deering, K.E. Ouellette, T.B. Montgomery, C. Wheelock, C.E. Casson, R.J. Williams, P.A. John, S.W.M. |
Citation: | Proceedings of the National Academy of Sciences of USA, 2020; 117(52):33619-33627 |
Publisher: | National Academy of Sciences |
Issue Date: | 2020 |
ISSN: | 0027-8424 1091-6490 |
Statement of Responsibility: | Jeffrey M. Harder, Chelsea Guymer, John P. M. Wood, Evangelia Daskalaki, Glyn Chidlow, Chi Zhang, Revathi Balasubramanian, Brynn H. Cardozo, Nicole E. Foxworth, Kelly E. Deering, Tionna B. Ouellette, Christa Montgomery, Craig E. Wheelock, Robert J. Casson, Pete A. Williams, and Simon W. M. John |
Abstract: | Intraocular pressure-sensitive retinal ganglion cell degeneration is a hallmark of glaucoma, the leading cause of irreversible blindness. Here, we used RNA-sequencing and metabolomics to examine early glaucoma in DBA/2J mice. We demonstrate gene expression changes that significantly impact pathways mediating the metabolism and transport of glucose and pyruvate. Subsequent metabolic studies characterized an intraocular pressure (IOP)-dependent decline in retinal pyruvate levels coupled to dysregulated glucose metabolism prior to detectable optic nerve degeneration. Remarkably, retinal glucose levels were elevated 50-fold, consistent with decreased glycolysis but possibly including glycogen mobilization and other metabolic changes. Oral supplementation of the glycolytic product pyruvate strongly protected from neurodegeneration in both rat and mouse models of glaucoma. Investigating further, we detected mTOR activation at the mechanistic nexus of neurodegeneration and metabolism. Rapamycin-induced inhibition of mTOR robustly prevented glaucomatous neurodegeneration, supporting a damaging role for IOP-induced mTOR activation in perturbing metabolism and promoting glaucoma. Together, these findings support the use of treatments that limit metabolic disturbances and provide bioenergetic support. Such treatments provide a readily translatable strategy that warrants investigation in clinical trials. |
Keywords: | glaucoma neuronal metabolism retinal ganglion cell neuroprotection pyruvate |
Description: | first published December 14, 2020; |
Rights: | © 2020 the Author(s). This open access article is distributed under Creative Commons Attribution-NonCommercial- NoDerivatives License 4.0 (CC BY-NC-ND). |
DOI: | 10.1073/pnas.2014213117 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1102568 |
Published version: | http://dx.doi.org/10.1073/pnas.2014213117 |
Appears in Collections: | Aurora harvest 4 Opthalmology & Visual Sciences publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_131008.pdf | Published version | 1.59 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.